Researchers at  the Institute for Research in Biomedicine (IRB Barcelona) and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and have described that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes. The work – published in Cancer Research– has also shown that between the initial tumour and the metastasis the subtype of breast cancer can change in up to 40% of cases.

The work (10.1158/0008-5472.CAN-16-2717) has been coordinated by Aleix Prat, Head of the Oncology Department of the Hospital Clínic, Head of the Translational Genomics team and directed therapies in solid tumors IDIBAPS team and Head of the VHIO Translational Genomics Group. The first author of the study is Juan Miguel Cejalvo, PhD student of the PhD4MD programme in the group led by Aleix Prat at IDIBAPS and in the Growth control and cancer metastasis group of the Institute for Research in Biomedicine (IRB Barcelona), led by the ICREA researcher Roger Gomis.

In breast cancer, metastases appear years or even decades after the diagnosis of the primary tumour. These secondary lesions originate from dispersed tumour cells that have gone through a period of dormancy. It is important to know the molecular mechanisms that promote the formation of detectable metastases from these disseminated cancerous cells for a more accurately approach of the disease.

Breast cancer can be classified in four subtypes at the molecular level: Luminal A, Luminal B, HER2-enriched (HER2-E) and basal-like type. There are great differences among them in terms of incidence, survival and response to different treatments. So far, the results of tumor analysis have suggested that the molecular subtype does not substantially change when metastases appear.

Researchers studied the genomic changes in 105 genes at the RNA level between the initial tumour and the metastases. They observed that, although in most cases the molecular subtype is maintained when the metastasis appears, this does not happen in a particular subtype, Luminal A. For the study, samples from 123 patients from a trial of the GEICAM, the Breast Cancer Research Group, and the hospitals Clínic of Barcelona, ​​Clínic of Valencia, Vall d’Hebron and AO-Papardo Of Messina (Italy), were analyzed.

This study also describes for the first time that the longer the time between the diagnosis of the primary tumour and the onset of metastasis is, the more aggressive becomes the cancer.

• More information: IRB Barcelona website [+]